Compare CVS Health Corp (CVS) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs L3Harris Technologies Inc — how do they compare? CVS Health Corp trades at $94.14 (market cap $119.58B), while L3Harris Technologies Inc trades at $283.5 (market cap $53.26B). The key difference: CVS Health Corp is far larger — about 2.2× L3Harris Technologies Inc's market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| CVS | LHX | |
|---|---|---|
Market Cap | $119.58B | $53.26B |
Sector | Health | Industrials |
52-Week High | $110.60 | $378.48 |
52-Week Low | $65.51 | $270.21 |
Enterprise Value | $181.93B | $63.71B |
Dividend Yield | 2.84% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
LHX trades at $289.72, up 1.06% on the day, with a bearish technical signal but strong fundamental momentum. Recent earnings beats, including Q2 2026 EPS of $3.13 versus $2.80 expected, and a record $42 billion backlog support growth. The company completed a strategic divestiture and secured key defense contracts, enhancing its positioning in missile defense and space systems.
Outlook is positive with analyst consensus price target of $319.33 implying ~10% upside, though technical indicators signal near-term caution. Risks include execution on production ramp-ups and defense budget volatility, but robust cash flow and dividend payments provide shareholder stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
